![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
June 11, 2024
A Spring Group Meeting recap; a milestone for TMIST; a new myeloMATCH treatment trial
June 11, 2024
This phase 2 study is testing two variations of the triplet combination of azacitidine, venetoclax, and gilteritinib compared to standard therapy
June 11, 2024
Dustin A. “Dusty” Deming, MD, is the young investigator of the year for the ECOG-ACRIN Cancer Research Group
June 11, 2024
The group is recognizing Dr. Wakelee for her sustained commitment to developing women’s careers in cancer medicine and advancing women investigators in ECOG-ACRIN
June 11, 2024
Summaries of five ECOG-ACRIN trials presented at the 2024 American Society of Clinical Oncology Annual Meeting
June 11, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
June 13, 2024
This randomized phase 3 trial is comparing treatment with chemotherapy alone or with immunotherapy